Dr. Lawrence, an American biogerontologist, brings unique qualifications to his research. With a Jurisprudence degree (UCLA Law), an MS in Psychology, and a Ph.D. in Nutritional Science, he has spent three decades focusing on human longevity research and interventions for optimal life and health span.

At the age of 78, Dr. Lawrence's research has profoundly impacted his aging process. His average telomere length, or “Cellular Age,” is equivalent to that of a 23-year-old. His “Epigenetic Age,” measured by the Horvath Epigenetic Clock (DNA/Methylation), is ten years less than his chronological age, resulting in a fifty percent reduction of all-cause mortality risk compared to his same-age peers. His annual biological rate of aging is twenty-one percent slower than his chronological yearly aging.

Dr. Lawrence is affiliated with the St. Petersburg Institute of Bioregulation and Gerontology (Russia). He is the administrator of two pioneering Russian and American longevity clinical studies, Telomerase Activation and DNA/Methylation Epigenetic Age Modification, which are at the forefront of longevity research.

At the 2025 HEALinc Global Summit, he will present data and evidence that Peptide Bioregulators, a groundbreaking development by Prof. Vladimir Khavinson of the St. Petersburg Institute, result in cellular reprogramming, tissue rejuvenation, and organ regeneration.